The DOI matches its Crossref record.
Result of high-dose imatinib mesylate in patients with Philadelphia chromosome—positive chronic myeloid leukemia after failure of interferon-α
Abstract
Imatinib at 400 mg daily is effective in chronic-phase chronic myeloid leukemia (CML) after interferon failure, although only a few patients achieve a molecular remission. We investigated whether higher doses of imatinib may be more effective. Thirty-six patients with chronic-phase CML after failure on interferon-α were treated with 400 mg imatinib twice daily. Median time from diagnosis was 25 months (range, 10-135 months); 4 patients (11%) had clonal evolution. All 11 patients with active disease achieved complete hematologic response. Excluding patients with fewer than 35% Ph-positive metaphases before the start of therapy, 19 (90%) of 21 evaluable patients achieved a major cytogenetic response. Of 27 evaluable patients, 24 (89%) achieved a complete cytogenetic response. Quantitative polymerase chain reaction was performed in bone marrow every 3 months. Of 32 evaluable patients, 18 (56%) showed BCR-ABL/ABL percentage ratios lower than 0.045%, including 13 (41%) with undetectable levels. With a median follow-up of 15 months, all patients were alive in chronic phase. Toxicities were similar to those reported with standard dose; 71% of patients continue to receive 600 mg or more of imatinib daily. In conclusion, high-dose imatinib induces complete cytogenetic responses in most patients with chronic-phase CML after interferon failure. This is accompanied by a high rate of molecular remission. (Blood. 2003;102:83-86)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Baccarani, M. (2006) · Blood · doi:10.1182/blood-2006-02-005686 · Cited by 1,277
The development of imatinib as a therapeutic agent for chronic myeloid leukemia
Deininger, M., Buchdunger, E., & Druker, B. J. (2005) · Blood · doi:10.1182/blood-2004-08-3097 · Cited by 1,253
Kantarjian, H., Talpaz, M., O'Brien, S., Garcia-Manero, G., Verstovsek, S., Giles, F., Rios, M. B., Shan, J., Letvak, L., Thomas, D., et al. (2004) · Blood · doi:10.1182/blood-2003-11-3800 · Cited by 392
Self-citationJabbour, E., Kantarjian, H., Jones, D., Talpaz, M., Bekele, N., O'Brien, S., Zhou, X., Luthra, R., Garcia-Manero, G., Giles, F., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404318 · Cited by 386
Self-citationImatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance
Hochhaus, A., & La Rosée, P. (2004) · Leukemia · doi:10.1038/sj.leu.2403426 · Cited by 336
Metadata
- Authors
- Cortes, J., Giles, F., O'Brien, S., Thomas, D., Garcia-Manero, G., Rios, M. B., Faderl, S., Verstovsek, S., Ferrajoli, A., Freireich, E. J., Talpaz, M., & Kantarjian, H.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2003-07-01
- Volume
- 102
- Issue
- 1
- Pages
- 83-86
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2151968496
- Cited by
- 188
- References
- 0
- FWCI
- 10.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Result of high-dose imatinib mesylate in patients with Philadelphia chromosome—positive chronic myeloid leukemia after failure of interferon-α. https://app.cochat.ai/papers/10.1182/blood-2003-01-0025
- The paper
- Cortes, J., Giles, F., O'Brien, S., Thomas, D., Garcia-Manero, G., Rios, M. B., Faderl, S., Verstovsek, S., Ferrajoli, A., Freireich, E. J., Talpaz, M., & Kantarjian, H. (2003). Result of high-dose imatinib mesylate in patients with Philadelphia chromosome—positive chronic myeloid leukemia after failure of interferon-α. Blood. https://doi.org/10.1182/blood-2003-01-0025
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.